Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 526 to 540 of 676 results for diabetes

  1. Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)

    Evidence-based recommendations on adalimumab (Humira) and dexamethasone (Ozurdex) for treating non-infectious uveitis in adults.

  2. Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis (TA1096)

    Evidence-based recommendations on benralizumab (Fasenra) for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis in adults.

  3. Dementia (QS184)

    This quality standard covers preventing dementia, and assessment, management and health and social care support for people with dementia. It describes high-quality care in priority areas for improvement.

  4. Mental health of adults in contact with the criminal justice system (NG66)

    This guideline covers assessing, diagnosing and managing mental health problems in adults (aged 18 and over) who are in contact with the criminal justice system. It aims to improve mental health and wellbeing in this population by establishing principles for assessment and management, and promoting more coordinated care planning and service organisation across the criminal justice system.

  5. Butterfly iQ+ for diagnostic ultrasound imaging (MIB254)

    NICE has developed a medtech innovation briefing (MIB) on Butterfly iQ+ for diagnostic ultrasound imaging .

  6. Suspected neurological conditions: recognition and referral (NG127)

    This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.

  7. Patiromer for treating hyperkalaemia (TA623)

    Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults.

  8. Sipavibart for preventing COVID-19 [ID6282]

    In development Reference number: GID-TA11352 Expected publication date: TBC

  9. Peezy Midstream for urine collection (MT446)

    In development Reference number: GID-MT538 Expected publication date: TBC

  10. Digital technologies for multidisciplinary weight management

    In development Reference number: GID-HTE10077 Expected publication date: TBC

  11. Diagnosis and management of type 1 diabetes in children, young people and adults (CG15)

    This guidance has been updated and replaced by NICE guidelines NG17, NG18 and NG19.

  12. Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis (HTG441)

    Evidence-based recommendations on multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis.

  13. MolecuLight i:X for wound imaging (MIB212)

    NICE has developed a medtech innovation briefing (MIB) on MolecuLight i:X for wound imaging .

  14. Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)

    Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (also known as Viekirax) with or without dasabuvir (also known as Exviera) for adults with some types (called genotypes) of chronic hepatitis C.

  15. Benralizumab for treating severe eosinophilic asthma (TA565)

    Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.